15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering GlaxoSmithKline PLC ADR, 1 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a hold consensus. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.43 next quarter toward $5.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy133%
Hold133%
Sell133%
Strong Sell00%
Based on 3 analysts giving stock ratings to GlaxoSmithKline PLC ADR.
As of Jul, 1 of 3 firms rate GSK a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
GSK EPS & revenue forecast
EPS · NEXT QUARTER
$1.43
Range $1.38 – $1.48 · 2 analysts · -2% YoY
Next period, 2 analysts expect GlaxoSmithKline PLC ADR to earn $1.43 a share (range $1.38 – $1.48), versus $1.46 a year earlier. Full-year consensus is $4.82, growing to $5.16 the year after.
REVENUE · NEXT QUARTER
$8.9B
Range $8.7B – $9.1B · 2 analysts · +4% YoY
Revenue is expected to reach $8.9B (range $8.7B – $9.1B), +4.5% year-over-year. Full-year consensus is $33.9B, rising to $35.7B next year.
Top analysts covering GlaxoSmithKline PLC ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GSK.
#1
EF
Emily Field
Barclays
Sell
No targeton GSK
Coverage
—
+ Follow
#2
JG
James Gordon
Barclays
Sell
No targeton GSK
Coverage
—
+ Follow
#3
SJ
Sachin Jain
Bank of America Securities
Sell
$1700.00+3065.1% to target
Coverage
—
+ Follow
#4
ML
Michael Leuchten
Jefferies
Buy
No targeton GSK
Coverage
—
+ Follow
#5
PW
Peter Welford
Jefferies
Hold
No targeton GSK
Coverage
—
+ Follow
GSK stock forecast FAQ
Is GSK stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
How many Wall Street analysts cover GSK?+
3 analysts have an active rating on GlaxoSmithKline PLC ADR.
Who is the most accurate analyst covering GSK?+
Among analysts who currently cover GSK, Emily Field of Barclays has the strongest overall Quantellect track record. Their current call is Sell.
What is GlaxoSmithKline PLC ADR's projected EPS for next quarter?+
The consensus estimate is $1.43 per share (range $1.38 – $1.48) across 2 analysts. Full-year EPS is projected at $4.82, rising to $5.16 the following year.
How much revenue is GlaxoSmithKline PLC ADR expected to report next quarter?+
Consensus revenue is $8.9B (range $8.7B – $9.1B). Full-year revenue is projected at $33.9B, growing to $35.7B next year.
Have analysts been upgrading or downgrading GSK lately?+
As of Jul, 1 of 3 firms rate GSK a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GSK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Citigroup
